PRACTICE PARAMETER 23 Radiation Oncology Proton Therapy
69. Lin H, Shi C, Huang S, et al. Applications of various range shifters for proton pencil beam scanning
radiotherapy. Radiat Oncol 2021;16:146.
70. Tilly N, Johansson J, Isacsson U, et al. The influence of RBE variations in a clinical proton treatment plan for
a hypopharynx cancer. Physics in medicine and biology 2005;50:2765-77.
71. Baldini EH, Wang D, Haas RL, et al. Treatment Guidelines for Preoperative Radiation Therapy for
Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel. International journal of
radiation oncology, biology, physics 2015;92:602-12.
72. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast
cancer. The New England journal of medicine 2013;368:987-98.
73. Dess RT, Sun Y, Matuszak MM, et al. Cardiac Events After Radiation Therapy: Combined Analysis of
Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer. Journal of clinical
oncology : official journal of the American Society of Clinical Oncology 2017;35:1395-402.
74. Luo L, Cuaron J, Braunstein L, et al. Early outcomes of breast cancer patients treated with post-mastectomy
uniform scanning proton therapy. Radiotherapy and oncology : journal of the European Society for Therapeutic
Radiology and Oncology 2019;132:250-56.
75. Mutter RW, Choi JI, Jimenez RB, et al. Proton Therapy for Breast Cancer: A Consensus Statement From the
Particle Therapy Cooperative Group Breast Cancer Subcommittee. International journal of radiation oncology,
biology, physics 2021;111:337-59.
76. Oonsiri P, Nantavithya C, Lertbutsayanukul C, et al. Dosimetric evaluation of photons versus protons in
postmastectomy planning for ultrahypofractionated breast radiotherapy. Radiat Oncol 2022;17:20.
77. Stick LB, Jensen MF, Bentzen SM, et al. Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy
for Synchronous Bilateral Breast Cancer. Int J Part Ther 2022;8:1-13.
78. Choi JI, Khan AJ, Powell SN, et al. Proton reirradiation for recurrent or new primary breast cancer in the
setting of prior breast irradiation. Radiotherapy and oncology : journal of the European Society for Therapeutic
Radiology and Oncology 2021;165:142-51.
79. Pasalic D, Strom EA, Allen PK, et al. Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a
Planned Interim Analysis of a Prospective Phase 2 Trial. International journal of radiation oncology, biology,
physics 2021;109:441-48.
80. Bekelman JE, Lu H, Pugh S, et al. Pragmatic randomised clinical trial of proton versus photon therapy for
patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp)
Consortium trial protocol. BMJ Open 2019;9:e025556.
81. Bradley JD, Hu C, Komaki RR, et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus
High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung
Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020;38:706-14.
82. Lazarev S, Rosenzweig K, Samstein R, et al. Where are we with proton beam therapy for thoracic
malignancies? Current status and future perspectives. Lung Cancer 2021;152:157-64.
83. Badiyan SN, Rutenberg MS, Hoppe BS, et al. Clinical Outcomes of Patients With Recurrent Lung Cancer
Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton
Therapy Institute Prospective Registry Studies. Pract Radiat Oncol 2019;9:280-88.
84. Chao HH, Berman AT, Simone CB, 2nd, et al. Multi-Institutional Prospective Study of Reirradiation with
Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. J Thorac Oncol
2017;12:281-92.
85. Hong JH, Kim YS, Lee SW, et al. High-Dose Thoracic Re-irradiation of Lung Cancer Using Highly Conformal
Radiotherapy Is Effective with Acceptable Toxicity. Cancer Res Treat 2019;51:1156-66.
86. McAvoy S, Ciura K, Wei C, et al. Definitive reirradiation for locoregionally recurrent non-small cell lung
cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity
and survival outcomes. International journal of radiation oncology, biology, physics 2014;90:819-27.
87. T.P. Kegelman HHC, C.B. Simone, C. Aggarwal, J. Bauml, A. Singh, W.P. Levin, K.A. Cengel, S.J.
Feigenberg, R. Rengan, C. Langer, C. Ciunci, J.P. Plastaras, A.T. Berman,. Long-term Update of Outcomes of
Proton Beam Re-irradiation for Locoregionally Recurrent Non-Small Cell Lung Cancer. International Journal
of Radiation Oncology*Biology*Physics 2020;108:e98.
88. Yang WC, Hsu FM, Chen YH, et al. Clinical outcomes and toxicity predictors of thoracic re-irradiation for
locoregionally recurrent lung cancer. Clin Transl Radiat Oncol 2020;22:76-82.
89. Chi A, Chen H, Wen S, Yan H, Liao Z. Comparison of particle beam therapy and stereotactic body
radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-